GSK plc (GSK) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Total Assets Chart for GSK plc
GSK plc (GSK) total assets for FY2025 were GBP 61.1B, a 2.8% change from FY2024. GSK plc's total assets grew from GBP 1.8B in 1986 to GBP 61.1B in 2025 (3289.8% over 39 years). Total assets compound annual growth rate: 5-year CAGR of -5.3%, 10-year CAGR of 1.4%, 20-year CAGR of 4.1%.
Total Assets (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £74.16B
- Implied Share Price
- £18.52
- Enterprise Value
- £87.93B
- Revenue (TTM)
- £33.20B
- EBITDA
- £10.82B
- Profit Margin
- 14.52%
- Trailing P/E
- 15.69
- Forward P/E
- 19.76
- Price/Book (MRQ)
- 4.13
- Price/Sales (TTM)
- 2.23
- EV/EBITDA
- 9.09
- EV/Revenue
- 2.65
- Dividend Yield
- 3.74%
- Book Value
- £4.40
- Free Cash Flow (FY2025)
- £5.96B
- Free Cash Flow Yield
- 8.03%
Snapshot as of 18th August 2026 — not point-in-time controlled, may lag the live market by a few days.